New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
10:55 EDTDYN, SLXP, VIP, NKTR, BDSI, CCIH, BNNY, USG, IDIX, ACHNHigh option volume stocks:
High option volume stocks: BNNY VIP ACHN CCIH SLXP IDIX BDSI DYN USG NKTR
News For BNNY;VIP;ACHN;CCIH;SLXP;IDIX;BDSI;DYN;USG;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
09:07 EDTUSGUSG distribution sales likely impacted by soft demand, say Cleveland Research
Subscribe for More Information
06:07 EDTACHNStocks with implied volatility above IV index mean; DG ACHN
Subscribe for More Information
November 24, 2014
16:08 EDTCCIHChinaCache announces strategic partnership with Aspera
ChinaCache (CCIH) announced that it has formed a strategic partnership with Aspera to provide best-performance high-speed data transmission services for large files. Aspera, an IBM (IBM) company, developed the technologies that move the world's data at maximum speeds. ChinaCache will combine its high quality CDN network service with Aspera's FASPô transmission technology to ensure high-speed transmission of large data files around the globe, with the added benefits of safety, controllability, cost-effectiveness and flexibility. The combination can increase the data transmission speed by 3 to 184 times, while enhancing the connectivity and stability of networks, as well as the security of data transmission.
10:14 EDTNKTRFDA grants QIDP designation to Bayer's Amikacin Inhale, Ciprofloxacin DPI
Subscribe for More Information
November 21, 2014
14:51 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
November 20, 2014
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
09:05 EDTNKTRNektar presents preclinical study findings for etirinotecan pegol combination
Nektar Therapeutics announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol in combination with the PARP inhibitor rucaparib in a BRCA1-deficient MX-1 breast tumor model. The preclinical study results demonstrated that all dose combinations of NKTR-102 and rucaparib were well-tolerated, synergistic, and led to 100% prolonged survival in this tumor model. These data were presented during the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. NKTR-102 and rucaparib in combination exhibited marked synergy, demonstrated by durable complete responses, even at the lowest doses of both agents dosed in combination. The combination of NKTR-102 and rucaparib was tolerated at all dose levels. Doses used in this study provide exposures of NKTR-102 and rucaparib that are achievable clinically, underscoring the translational relevance of these results. Combination studies of NKTR-102 and rucaparib are ongoing in patient-derived xenograft models in collaboration with Professor Paul Haluska at Mayo Clinic and Clovis Oncology.
November 19, 2014
07:09 EDTBDSIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
05:44 EDTACHNStocks with implied volatility movement; MCD KO
Subscribe for More Information
05:26 EDTVIPVimpelCom announces partnership with Twitter
Subscribe for More Information
November 14, 2014
11:38 EDTUSGUSG management to meet with SunTrust
Meeting to be held in Atlanta on November 19 hosted by SunTrust.
11:37 EDTUSGUSG management to meet with Wedbush
Subscribe for More Information
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.
November 12, 2014
09:11 EDTDYNDynegy management to meet with Deutsche Bank
Meeting to be held in Dallas on November 12 hosted by Deutsche Bank.
07:53 EDTNKTRLeerink to hold a tour
Subscribe for More Information
05:54 EDTACHNStocks with implied volatility movement; ACHN FXY
Subscribe for More Information
05:38 EDTVIPVimpelCom confirms FY14 revenue decline of low to mid-single digit vs. last year
Subscribe for More Information
05:36 EDTVIPVimpelCom reports Q3 EPS 6c vs. 15c last year
Reports Q3 revenue $5.15B vs. $5.69M last year. Mobile customer base increased 5M year-over-year to 223.4M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use